“Can’t you just take a pill?” is a question most of us have heard again and again whenever we take an injection or show off our insulin pump to family, friends, or strangers. Taking insulin orally has been a wish of PWDs for many years, but the “non-invasive dream” goes about as far as the stomach acid destroying the hormone before it reaches your blood stream.
Injecting insulin subcutaneously has been the only option considered…
Read more »
Finding a less invasive method of taking insulin seems to be all the rage these days. Although the once-hailed Exhubera fizzled away, researchers have not given up on the “holy grail” of oral insulin. Aside from Mannkind’s Afrezza, which is delayed and controversial, there’s another kind of oral insulin that might be making its mark in the diabetes marketplace… eventually.
Meet MonoSol Rx.
This New Jersey-based company has created PharmFilm, a thin, postage-sized film that…
Read more »
Last week, the New York Chapter of the Juvenile Diabetes Research Foundation hosted their annual research briefing. Many chapters around the country host similar research briefings, and I was excited to find out that our local meeting would feature Dr. Sanjoy Dutta, Director of Glucose Control Therapies within the Treatment Therapies Program.
I want to note that although there’s been a lot of controversy surrounding the addition of treatment goals to JDRF’s mission, I whole-heatedly…
Read more »
By
AmyT on
January 24, 2011
I can’t help it. This reminds me of the movie City Slickers, in which one of the characters has messed up his life, and his friends tell him he’s getting a “do-over.” The young company Dance Pharmaceuticals, based in downtown San Francisco, is basically on a mission to salvage the good parts of Pfizer’s failed inhaled insulin Exubera (not the awkward delivery device!) and launch a second coming of the base product that is “simpler,…
Read more »
By
AmyT on
January 17, 2011
Last week, thousands of healthcare companies and investors therein descended upon San Francisco for the 2011 JP Morgan Healthcare Conference. Although I wasn’t able to attend personally, I’ve been keeping an eagle eye on what happened there in terms of diabetes through my friend, seasoned industry observer David Kliff of Diabetic Investor — reporting daily on what he calls “the wacky world of diabetes devices.”
He’s kindly given me permission to summarize some of his…
Read more »
